- Home
- RLAY vs OXLCO Comparison
RLAY vs OXLCO Comparison
Compare RLAY & OXLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- OXLCO
- Stock Information
- Founded
- RLAY 2015
- OXLCO N/A
- Country
- RLAY United States
- OXLCO United States
- Employees
- RLAY N/A
- OXLCO N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- OXLCO Investment Managers
- Sector
- RLAY Health Care
- OXLCO Finance
- Exchange
- RLAY Nasdaq
- OXLCO Nasdaq
- Market Cap
- RLAY 576.1M
- OXLCO N/A
- IPO Year
- RLAY 2020
- OXLCO N/A
- Fundamental
- Price
- RLAY $3.60
- OXLCO $23.18
- Analyst Decision
- RLAY Strong Buy
- OXLCO
- Analyst Count
- RLAY 11
- OXLCO 0
- Target Price
- RLAY $18.40
- OXLCO N/A
- AVG Volume (30 Days)
- RLAY 1.6M
- OXLCO N/A
- Earning Date
- RLAY 08-05-2025
- OXLCO N/A
- Dividend Yield
- RLAY N/A
- OXLCO N/A
- EPS Growth
- RLAY N/A
- OXLCO N/A
- EPS
- RLAY N/A
- OXLCO N/A
- Revenue
- RLAY $7,679,000.00
- OXLCO N/A
- Revenue This Year
- RLAY $14.31
- OXLCO N/A
- Revenue Next Year
- RLAY N/A
- OXLCO N/A
- P/E Ratio
- RLAY N/A
- OXLCO N/A
- Revenue Growth
- RLAY N/A
- OXLCO N/A
- 52 Week Low
- RLAY $1.78
- OXLCO N/A
- 52 Week High
- RLAY $10.72
- OXLCO N/A
- Technical
- Relative Strength Index (RSI)
- RLAY 62.39
- OXLCO 56.39
- Support Level
- RLAY $3.10
- OXLCO $23.00
- Resistance Level
- RLAY $3.37
- OXLCO $23.29
- Average True Range (ATR)
- RLAY 0.24
- OXLCO 0.11
- MACD
- RLAY 0.02
- OXLCO 0.01
- Stochastic Oscillator
- RLAY 80.52
- OXLCO 76.60
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About OXLCO Oxford Lane Capital Corp. Preferred Stock Shares 6.00% Series 2029
Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.